ISRCTN61821827 https://doi.org/10.1186/ISRCTN61821827

Direct sputum sensitivity testing (DSST) in cystic fibrosis

Submission date	Recruitment status	[ ] Prospectively registered
12/09/2003	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
12/09/2003	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
16/03/2016	Nutritional, Metabolic, Endocrine	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr David Serisier

Contact details
Adult Cystic Fibrosis Unit,
Level D, West Wing (Room WD48)
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD
+44 (0)23 80794719
dserisier@hotmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0231103375

Study information

Scientific Title
Direct sputum sensitivity testing (DSST) in cystic fibrosis

Study objectives
Does direct sputum sensitivity testing in cystic fibrosis patients alter antibiotic prescribing and improve clinical outcomes?

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised double blinf controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Diagnostic

Participant information sheet

Health condition(s) or problem(s) studied
Cystic fibrosis

Interventions
Double blind, randomised controlled trial of DSST versus usual antibiotic sensitivity testing in cystic fibrosis patients with infective exacerbations requiring IV antibiotics.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Duration of IV antibiotic therapy.

Secondary outcome measures

1. Lung function
2. Quality of life
3. Antibiotic drug costs.

Overall study start date
01/04/2001

Completion date
31/03/2006

Eligibility

Key inclusion criteria
Cystic fibrosis patients (with infective exacerbations requiring IV antibiotics) who are colonised with Pseudonomas or Burkholderia.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
01/04/2001

Date of final enrolment
31/03/2006

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

Adult Cystic Fibrosis Unit,
Southampton
United Kingdom
SO16 6YD

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Southampton University Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration